https://doi.org/10.24875/RECICE.M26000628

SUPPLEMENTARY TABLES

Table S1, No-reflow cases

Case	Age	Presentation	Target vessel	Balloon size (mm)	Calcium Modulation	DCB drug	DCB brand	Number of DCBs used	Final TIMI flow
1	59	CCS	LAD	3.5x20	No	Paclitaxel	Pantera Lux	3	2
2	57	STEMI	RCA (ISR)	4.0x12	No	Paclitaxel	Pantera Lux	2	2
3	83	NSTEMI	Dg1	3.0x30	No	Paclitaxel	SeQuent Please	1	3
4	57	STEMI	RCA (ISR)	4.5x20	No	Paclitaxel	Pantera Lux	2	2
5	69	NSTEMI	LAD	4.0x30	No	Paclitaxel	Agent	2	2
6	56	CCS	LAD	2.5x25	Yes	Paclitaxel	SeQuent Please	2	2
7	86	NSTEMI	LM	3.0x25	No	Paclitaxel	Pantera Lux	2	2
8	45	CCS	RCA	2.5x25	Yes	Paclitaxel	Pantera Lux	2	2
9	56	NSTEMI	LAD	2.5x15	No	Paclitaxel	Pantera Lux	1	3
10	53	NSTEMI	RCA	4.0x30	No	Paclitaxel	Agent	1	3
11	53	NSTEMI	PDA	2.5x15	No	Paclitaxel	Pantera Lux	1	3
12	76	NSTEMI	PDA	2.5x15	No	Paclitaxel	Pantera Lux	1	1
13	66	CCS	LAD	3.0x20	No	Paclitaxel	Pantera Lux	1	0
14	66	CCS	LAD	2.0x30	Yes	Paclitaxel	Pantera Lux	2	2
15	69	NSTEMI	LAD (ISR)	4.0x30	Yes	Paclitaxel	Agent	2	2
16	56	CCS	LAD	2.5x25	Yes	Paclitaxel	SeQuent Please	2	2
17	86	STEMI	LM (ISR)	3.0x25	No	Paclitaxel	Pantera Lux	2	3
18	45	CCS	RCA	3.5x25	Yes	Paclitaxel	Pantera Lux	1	2
19	56	NSTEMI	LAD	2.5x15	No	Paclitaxel	Pantera Lux	1	2
20	86	STEMI	LAD	3.0x25	No	Paclitaxel	Pantera Lux	1	3
21	45	CCS	RCA	3.5x25	Yes	Paclitaxel	Pantera Lux	1	2
22	56	STEMI	LAD (ISR)	2.5x15	No	Paclitaxel	Pantera Lux	1	2
23	66	CCS	Dg1	3.0x20	No	Paclitaxel	Pantera Lux	1	3
24	75	CCS	LAD	2.0x30	No	Paclitaxel	Pantera Lux	1	2
25	89	STEMI	LAD (ISR)	2.5X25	No	Paclitaxel	Agent	1	2
26	51	NSTEMI	RCA	3.5x35	No	Paclitaxel	SeQuent Please	2	2
27	78	CCS	LAD	2.5x20	No	Paclitaxel	Pantera Lux	1	2
28	76	NSTEMI	LAD	3.0x25	No	Paclitaxel	Pantera Lux	2	2
29	66	CCS	LAD	2.5x30	No	Paclitaxel	Pantera Lux	2	3
30	52	STEMI	RCA (ISR)	4.0x30	No	Paclitaxel	Pantera Lux	2	2
31	83	NSTEMI	RCA	3.5x20	No	Paclitaxel	Agent	1	3
32	60	CCS	LAD (ISR)	3.0x35	No	Paclitaxel	SeQuent Please	1	2
33	77	CCS	LAD (ISR)	2.5X25	No	Paclitaxel	Agent	2	3
34	68	NSTEMI	PDA	2.5x30	No	Paclitaxel	Pantera Lux	1	3
35	72	CCS	LAD	3.0x25	No	Paclitaxel	Pantera Lux	2	2
36	65	NTSEMI	PDA	3.5x30	No	Sirolimus	Magic Touch	1	2

CCS: chronic coronary syndrome; DCB: drug coated balloon; ISR: in-stent restenosis; LAD: left anterior descending; NSTEMI: non-ST-segment elevation myocardial infarction; PDA: posterior descending artery; RCA: right coronary artery; STEMI: ST-segment elevation myocardial infarction; TIMI: Thrombolysis in Myocardial Infarction

https://doi.org/10.24875/RECICE.M26000628

Table S2. Cox proportional hazards model for all-cause death at 1-year

Variable	Hazard ratio	95%CI	*P*-value
Paclitaxel (vs Sirolimus)	0.89	0.46-1.71	0.722
Age (in years)	0.99	0.96-1.02	0.509
Diabetes mellitus	1.34	0.71-2.56	0.372
Current smoker	1.57	0.60-4.11	0.355
Acute presentation	1.06	0.55-2.05	0.871
Multivessel disease	1.49	0.50-4.41	0.480
Multivessel PCI	1.70	0.56-5.15	0.354
Severe calcification	1.23	0.87-3.64	0.299
Target lesion ISR	1.35	0.91-2.79	0.407
Target lesion CTO	1.03	0.66-9.02	0.178
Reference lumen diameter (in mm)	0.91	0.73-3.44	0.302
Bifurcation	1.32	0.80-4.43	0.388
Severe dissection after DCB	1.10	0.67-1.99	0.859

CTO: chronic total occlusion; DCB: drug coated balloon; ISR: in-stent restenosis;

PCI: percutaneous coronary intervention.

https://doi.org/10.24875/RECICE.M26000628

Table S3. Cox proportional hazards model for cardiovascular death at 1-year

Variable	Hazard ratio	95%CI	*P*-value
Paclitaxel (vs Sirolimus)	0.98	0.39-2.45	0.965
Age (in years)	1.00	0.96-1.04	0.510
Diabetes mellitus	1.20	0.46-3.12	0.707
Current smoker	1.57	0.60-4.11	0.357
Acute presentation	1.31	1.17-1.90	0.021
Multivessel disease	2.88	0.77-10.7	0.118
Multivessel PCI	0.30	0.09-0.95	0.041
Severe calcification	0.91	0.30-2.72	0.855
Target lesion ISR	1.34	0.71-2.56	0.369
Target lesion CTO	1.17	0.90-2.88	0.433
Reference lumen diameter (in mm)	1.24	0.41-3.72	0.699
Bifurcation	1.06	0.55-2.05	0.865
Severe dissection after DCB	1.70	0.56-5.15	0.348

CTO: chronic total occlusion; DCB: drug coated balloon; ISR: in-stent restenosis;

PCI: percutaneous coronary intervention.

https://doi.org/10.24875/RECICE.M26000628

Table S4. Cox proportional hazards model for TL-MI at 1-year

Variable	Hazard ratio	95%CI	*P*-value
Paclitaxel (vs Sirolimus)	1.09	0.56-2.12	0.783
Age (in years)	0.98	0.95-1.01	0.186
Diabetes mellitus	2.35	1.16-4.77	0.018
Current smoker	0.40	0.13-1.18	0.097
Acute presentation	1.17	0.59-2.29	0.657
Multivessel disease	1.82	0.72-4.61	0.211
Multivessel PCI	0.29	0.13-0.65	0.002
Severe calcification	1.44	0.49-2.04	0.723
Target lesion ISR	1.32	0.74-3.01	0.518
Target lesion CTO	1.12	0.53-2.18	0.701
Reference lumen diameter (in mm)	1.39	0.88-2.98	0.626
Bifurcation	1.23	0.58-2.34	0.669
Severe dissection after DCB	1.19	0.63-2.74	0.495

CTO: chronic total occlusion; DCB: drug coated balloon; ISR: in-stent restenosis;

PCI: percutaneous coronary intervention; TL-MI: target lesion myocardial infarction.

https://doi.org/10.24875/RECICE.M26000628

Table S5. Cox proportional hazards model for TLR at 1-year

Variable	Hazard ratio	95%CI	*P*-value
Paclitaxel (vs Sirolimus)	1.10	0.59-2.06	0.772
Age (in years)	1.02	0.99-1.06	0.161
Diabetes mellitus	1.31	0.63-2.71	0.468
Current smoker	0.28	0.07-1.12	0.073
Acute presentation	1.16	0.57-2.36	0.694
Multivessel disease	1.11	0.72-2.34	0.574
Multivessel PCI	1.35	0.69-1.76	0.324
Severe calcification	1.16	0.43-3.13	0.768
Target lesion ISR	1.76	0.86-3.57	0.122
Target lesion CTO	2.84	1.10-7.37	0.032
Reference lumen diameter (in mm)	0.99	0.94-1.06	0.862
Bifurcation	0.59	0.25-1.39	0.238
Severe dissection after DCB	3.92	1.64-9.38	0.002

CTO: chronic total occlusion; DCB: drug coated balloon; ISR: in-stent restenosis;

PCI: percutaneous coronary intervention; TLR: target lesion revascularization.

https://doi.org/10.24875/RECICE.M26000628

Table S6. Cox proportional hazards model for TLF at 1-year

Variable	Hazard ratio	95%CI	*P*-value
Paclitaxel (vs Sirolimus)	1.22	0.71-2.10	0.474
Age (in years)	1.00	0.98-1.03	0.873
Diabetes mellitus	1.31	0.74-2.33	0.347
Current smoker	0.59	0.34-1.48	0.324
Acute presentation	1.41	0.97-2.66	0.064
Multivessel disease	1.22	0.84-1.79	0.411
Multivessel PCI	1.70	0.56-4.12	0.392
Severe calcification	1.14	0.47-2.76	0.770
Target lesion ISR	1.70	1.04-3.00	0.039
Target lesion CTO	1.37	0.51-3.66	0.533
Reference lumen diameter (in mm)	1.07	1.04-1.10	< 0.001
Bifurcation	1.26	0.70-2.27	0.437
Severe dissection after DCB	3.43	1.67-7.02	< 0.001

CTO: chronic total occlusion; DCB: drug coated balloon; ISR: in-stent restenosis;

PCI: percutaneous coronary intervention; TLF: target lesion failure.

https://doi.org/10.24875/RECICE.M26000628

Table S7. Distribution of inverse probability of treatment weights


Group	Raw N	Weighted N	EES	Median weight	IQR weight	Max weight
Agent	104	645.2	182	5.1	3.2-7.4	14.8
Pantera Lux	295	657.8	401	2.0	1.4-3.0	7.3
SeQuent Please	124	658.4	210	4.6	3.0-6.9	12.5
Magic Touch	189	691.6	245	3.4	2.1-5.6	11.8
Selution	492	661.6	420	1.3	0.9–1.9	6.9

IPTW: inverse probability of treatment weighting. Weighted N corresponds to the sum of IPTW weights.

Effective sample size (ESS) was calculated as $(\sum w)^2/\sum w^2$. Extreme weights were truncated at the 1st and 99th percentiles.

https://doi.org/10.24875/RECICE.M26000628

Figure S1. Love plot of covariate balance before and after IPTW (Paclitaxel).



https://doi.org/10.24875/RECICE.M26000628

Figure S2. Love plot of covariate balance before and after IPTW (Sirolimus.

